Standards of medical care for patients with diabetes mellitus

Diabetes Care

Volumn 26, Issue SUPPL. 1, 2003, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; INSULIN; METFORMIN; NICOTINIC ACID; PNEUMOCOCCUS VACCINE; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN;

AMPUTATION; ANAMNESIS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC DIET; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIAGNOSTIC APPROACH ROUTE; DIET THERAPY; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ENTERIC COATED TABLET; EXERCISE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IMMUNIZATION; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; META ANALYSIS; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT REFERRAL; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; REVIEW; REYE SYNDROME; RHABDOMYOLYSIS; RISK FACTOR; SCREENING; SCREENING TEST; SECONDARY PREVENTION; SELF MONITORING; SIDE EFFECT; SMOKING CESSATION; STANDARD;

EID: 0003187466     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.2007.s33     Document Type: Review

References (106)

1. Skyler JS (Ed.): Medical Management of Type 1 Diabetes. 3rd ed. Alexandria, VA, American Diabetes Association, 1998
2. Zimmerman BR (Ed.): Medical Management of Type 2 Diabetes, 4th ed. Alexandria, VA, American Diabetes Association, 1998
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26 (Suppl. 1):S5-S20, 2003
4. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaaniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
5. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the DaQing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
6. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
7. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
8. Sjostrom L, et al: XENDOS (Xenical in the prevention of diabetes in obese subjects): a landmark study. Poster presented at the International Congress on Obesity (ICO), San Paulo, Brazil, 2002
9. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological trewatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796-2803, 2002
10. Engelgau ME, Narayan KMV, Herman WH: Screening for type 2 diabetes (Technical Review). Diabetes Care 23:1563-1580, 2000 [erratum appears in Diabetes Care 23:1868-1869, 2000]
11. American Diabetes Association: Type 2 diabetes in children and adolescents (Consensus Statement). Diabetes Care 23:381-389, 2000
12. American Diabetes Association: Gestational diabetes mellitus (Position Statement). Diabetes Care 26 (Suppl. 1): S103-S105, 2003
13. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
14. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
15. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
16. DCCT/EDIC Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
17. Lawson ML, Gerstein HC, Tsui E, Zinman B: Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. Diabetes Care 22 (Suppl. 1):B35-B39, 1999
18. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
19. American Diabetes Association: Postprandial blood glucose (Consensus Statement). Diabetes Care 24:775-778, 2001
20. Jovanovic L (Ed.): Medical Management of Pregnancy Complicated by Diabetes. 3rd ed. Alexandria, VA, American Diabetes Association, 2000
21. American Diabetes Association: Hyperglycemic crises in patients with diabetes mellitus (Position Statement). Diabetes Care 26 (Suppl. 1):S109-S117, 2003
22. Malmberg K for the DIGAMI Study Group: Prospective randomized study of intensive insulin treatment on long term survival after myocardial infarction in patients with diabetes. BMJ 314:512-515, 1997
23. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients, N Engl J Med 345:1359-1367, 2001
24. American Diabetes Association: Self-monitoring of blood glucose (Consensus Statement). Diabetes Care 17:81-86, 1994
25. American Diabetes Association: Self-monitoring of blood glucose (Consensus Statement). Diabetes Care 10:93-99, 1987
26. Sacks DB, Bruns DE, Goldstein DE, MacLaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 25:750-786, 2002
27. 1c in the Diabetes Contrrol and Complications Trial. Diabetes Care 25:275-278, 2002
28. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister L, Hoogwerf BJ, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Technical Review). Diabetes Care 25:148-198, 2002
29. American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). Diabetes Care 26 (Suppl. 1):S51-S61, 2003
30. Schneider SH, Ruderman NB: Exercise and NIDDM (Technical Review). Diabetes Care 13:785-789, 1990
31. Wasserman DH, Zinman B: Exercise in individuals with IDDM (Technical Review). Diabetes Care 17:924-937, 1994
32. Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes mellitus (Technical Review). Diabetes Care 25:134-147, 2002
33. Haffner SM: Management of dyslipidemia in adults with diabetes (Technical Review). Diabetes Care 21:160-178, 1998
34. Colwell JA: Aspirin therapy in diabetes (Technical Review). Diabetes Care 20:1767-1771, 1997
35. Haire-Joshu D, Glasgow RE, Tibbs TL: Smoking and diabetes (Technical Review). Diabetes Care 22:1887-1898, 1999
36. American Diabetes Association: Consensus development conference on the diagnosis of coronary heart disease in people with diabetes (Consensus Statement). Diabetes Care 21:1551-1559, 1998
37. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Int Med 157:2413-2446, 1997
38. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
39. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D,Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial: HOT Study Group. Lancet 351:1755-1762, 1998
40. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med 336:1117-1124, 1997
41. Tatti P, Paahron M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998
42. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-654, 1998
43. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet 355:253-259, 2000
44. Progress Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
45. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967-1975, 2000
46. Pyorala K, Pedersen TR, Kjeksus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Study (4S). Diabetes Care 20:614-620, 1997
47. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction I patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335:1001-1009, 1996
48. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349-1357, 1998
49. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622, 1998
50. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
51. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary, heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999
52. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
53. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA 284:1263-1270, 2000
54. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 162:1568-1576, 2002
55. Expert Panel on Blood Cholesterol Levels in Children and Adolescents: Treatment recommendations of the National Cholesterol Education Program Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89 (Suppl.):525-584, 1992
56. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Amplified benefit of clopidogrel versus aspirin in patientrs with diabetes mellitus. Am J Cardiol 90:625-628, 2002
57. US Preventive Services Task Force: Counseling to prevent tobacco use. In Guide to Clinical Preventive Services. 2nd ed. Baltimore, MD, Williams & Wilkins, 1996, p. 597-609
58. Fiore M, Bailey W, Cohen S: Smoking Cessation: Clinical Practice Guideline Number 18. Rockville, MD, US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996
59. Garg J, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. J Vasc Med 7:35-43, 2002
60. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314:783-788, 1997
61. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 156:286-289, 1996
62. Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
63. The DCCT Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial (DCCT). Kidney Int 47:1703-1720, 1995
64. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
65. Laffel LMB, McGill JB, Gans DJ, the North American Microalbuminuria Study Group (NAMSG): The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 99:497-504, 1995
66. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
67. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 156:286-289, 1996
68. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
69. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
70. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
71. Anderson S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57:601-606, 2000
72. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Disease 39 (Suppl. 2):SI-S246, 2002
73. Levey S, Bosch J, Lewis B, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999
74. Levinsky N: Specialist of evaluation in chronic kidney disease: too little, too late. Ann Intern Med 137:542-543, 2002
75. American Diabetes Association: Diabetic nephropathy (Position Statement). Diabetes Care 26 (Suppl. 1):S94-S98, 2003
76. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL, Klein R: Diabetic retinopathy (Technical Review). Diabetes Care 21:143-156, 1998
77. The Diabetes Control and Complications Trial Research Group: Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care 23:1084-1091, 2000
78. Diabetic Retinopathy Study Research Group: Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 81:383-396, 1976
79. Diabetic Retinopathy Study Research Group: Four risk factors for severe visual loss in diabetic retinopathy: the third report of the Diabetic Retinopathy Study. Arch Opthalmol 97:654-655, 1979
80. Diabetic Retinopathy Study Research Group: Design, methods, and baseline results: DRS report no. 6. Invest Ophthalmol Vis Sci 21:149-209, 1981
81. Diabetic Retinopathy Study Research Group: Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings: DRS report number 8. Opthalmology 88:583-600, 1981
82. Diabetic Retinopathy Study Research Group: Indications for photocoagulation treatment of diabetic retinopathy: DRS report no. 14. Int Opthalmol Clin 27:239-253, 1987
83. Early Treatment Diabetic Retinopathy Stud), Research Group: Photocoagulation for diabetic macular edema: ETDRS report no. 1. Arch Opthalmol 103:1796-1806, 1985
84. Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: ETDRS report number 2. Opthalmology 94:761-774, 1987
85. Early Treatment Diabetic Retinopathy Study Research Group: Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: ETDRS report no. 3. Int Ophthalmol Clin 27:254-264, 1987
86. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: ETDRS report no. 4. Int Opthalmol Clin 27:265-272, 1987
87. Early Treatment Diabetic Retinopathy: Study design and baseline patient characteristics: ETDRS report number 7. Opthalmology 98:741-756, 1991
88. Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Opthalmology 98 (Suppl.):757-765, 1991
89. Early Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy: ETDRS report no. 9. Opthalmology 98:766-785, 1991
90. American Diabetes Association: Diabetic retinopathy (Position Statement). Diabetes Care 26 (Suppl. 1):S99-S102, 2003
91. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM: Preventive foot care in people with diabetes (Technical Review). Diabetes Care 21:2161-2177, 1998
92. American Diabetes Association: Preventive foot care in people with diabetes (Position Statement). Diabetes Care 26 (Suppl. 1):S78-S79, 2003
93. American Diabetes Association: Consensus Development Conference on Diabetic Foot Wound Care (Consensus Statement). Diabetes Care 22:1354-1360, 1999
94. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD: Preconception care of diabetes: glycemic control prevents excess congenital malformations. JAMA 265:731-736, 1991
95. Goldman JA, Dicker D, Feldberg D, Yeshaya A, Samuel N, Karp M: Pregnancy outcome in patients with insulin-dependent diabetes mellitus with preconception diabetic control: a comparative study. Am J Obstet Gynecol 155:293-297, 1986
96. Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA: Pre-conception management of insulin-dependent diabetes: improvement of pregnancy outcome. Obstet Gynecol 77:846-849, 1991
97. Tchobroutsky C, Vray MM, Altman JJ: Risk/benefit ratio of changing late obstetrical strategies in the management of insulin-dependent diabetic pregnancies. Diabete Metab 17:287-294, 1991
98. Willhoite MB, Bennert HW Jr, Palomaki GE, Zaremba MM, Herman WH, Williams JR, Spear NH: The impact of preconception counseling on pregnancy outcomes. Diabetes Care 16:450-455, 1993
99. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner R: Pre-conception care of diabetes, congenital malformations, and spontaneous abortions (Technical Review). Diabetes Care 19:514-541, 1996
100. American Diabetes Association: Preconception care of women with diabetes (Position Statement). Diabetes Care 26 (Suppl. 1):S91-S93, 2003
101. Colquhoun AJ, Nicholson KG, Botha NT: Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 119:335-341, 1997
102. Centers for Disease Control and Prevention: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 51 (no. RR-3), 2002
103. Centers for Disease Control and Prevention: Prevention and control of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 46 (no. RR-08), 1997
104. Smith SA, Poland GA: The use of influenza and pneumococcal vaccines in people with diabetes (Technical Review). Diabetes Care 23:95-108, 2000
105. American Diabetes Association: Immunization and the prevention of influenza and pneumococcal disease in people with diabetes (Position Statement). Diabetes Care 26 (Suppl. 1):S126-S128, 2003
106. American Diabetes Association: Care of children with diabetes in the school and day care setting (Position Statement). Diabetes Care 26 (Suppl. 1):S131-S135, 2003